Alison Halliday, PhD, Technology Networks | May 19, 2023 | 5 min read
Gaining a better understanding of the dynamic and reciprocal interactions between cancer cells and the tumor microenvironment is essential for improving patient diagnosis and treatment.
Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company which provides biological research reagents and related technical contract research services, announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext under the stock abbreviation Sino Biological and stock code 301047. A total of 17 million shares were issued for a total of 4.98 billion RMB raised during this initial public offering.
Beyond The Scientist’s coverage of COVID-19’s molecular underpinnings were many other stories highlighting the advances made in scientists’ understanding of the biology of cells.
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.